About Paradox Immunotherapeutics
Paradox Immunotherapeutics is a company based in Toronto (Canada) founded in 2019 by Yulong Sun.. Paradox Immunotherapeutics has raised $7.03 million across 1 funding round from investors including SymBiosis. Paradox Immunotherapeutics offers products and services including LX-96, KX-99, and NX-86. Paradox Immunotherapeutics operates in a competitive market with competitors including Moderna, BridgeBio, BeiGene, Spark Therapeutics and Incyte, among others.
- Headquarter Toronto, Canada
- Founders Yulong Sun
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$7.03 M (USD)
in 1 rounds
-
Latest Funding Round
$7.03 M (USD), Series A
Feb 25, 2025
- Investors
-
Employee Count
Employee Count
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Paradox Immunotherapeutics
Paradox Immunotherapeutics offers a comprehensive portfolio of products and services, including LX-96, KX-99, and NX-86. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Antibody treatment targeting specific protein misfolding diseases.
Therapeutic for protein misfolding conditions in development.
Pipeline antibody for treating related protein disorders.
Funding Insights of Paradox Immunotherapeutics
Paradox Immunotherapeutics has successfully raised a total of $7.03M through 1 strategic funding round. The most recent funding activity was a Series A round of $7.03 million completed in February 2025. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 1
- Last Round Series A — $7.0M
-
First Round
First Round
(25 Feb 2025)
- Investors Count 1
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Feb, 2025 | Amount | Series A - Paradox Immunotherapeutics | Valuation |
investors |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Paradox Immunotherapeutics
Paradox Immunotherapeutics has secured backing from 1 investor, including venture fund investors. Prominent investors backing the company include SymBiosis. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Investments in healthcare companies are made by SymBiosis.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Paradox Immunotherapeutics
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Paradox Immunotherapeutics
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Paradox Immunotherapeutics Comparisons
Competitors of Paradox Immunotherapeutics
Paradox Immunotherapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Moderna, BridgeBio, BeiGene, Spark Therapeutics and Incyte, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
mRNA-based therapeutics for diseases including cancer and infections are developed.
|
|
| domain | founded_year | HQ Location |
Therapeutics for genetic diseases are developed through targeted interventions.
|
|
| domain | founded_year | HQ Location |
Targeted and immune-oncology drugs for cancer treatment are developed.
|
|
| domain | founded_year | HQ Location |
Gene therapies for rare diseases including retinal dystrophies are developed.
|
|
| domain | founded_year | HQ Location |
Small molecules are developed for cancer and skin disease treatments.
|
|
| domain | founded_year | HQ Location |
Developer of peptide therapeutics for the treatment of rare genetic deficiencies
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Paradox Immunotherapeutics
Frequently Asked Questions about Paradox Immunotherapeutics
When was Paradox Immunotherapeutics founded?
Paradox Immunotherapeutics was founded in 2019 and raised its 1st funding round 6 years after it was founded.
Where is Paradox Immunotherapeutics located?
Paradox Immunotherapeutics is headquartered in Toronto, Canada. It is registered at Toronto, Ontario, Canada.
Is Paradox Immunotherapeutics a funded company?
Paradox Immunotherapeutics is a funded company, having raised a total of $7.03M across 1 funding round to date. The company's 1st funding round was a Series A of $7.03M, raised on Feb 25, 2025.
What does Paradox Immunotherapeutics do?
Founded in 2019 and based in Toronto, Canada, the company operates in the biotechnology sector. A drug design platform is utilized to create monoclonal antibody treatments for protein misfolding diseases. The pipeline features LX-96 for heart failure, KX-99 for ALECT2 amyloidosis, and NX-86 for neurodegenerative diseases, with a focus on rare disease therapies.
Who are the top competitors of Paradox Immunotherapeutics?
Paradox Immunotherapeutics's top competitors include Moderna, Spark Therapeutics and BridgeBio.
What products or services does Paradox Immunotherapeutics offer?
Paradox Immunotherapeutics offers LX-96, KX-99, and NX-86.
Who are Paradox Immunotherapeutics's investors?
Paradox Immunotherapeutics has 1 investor. Key investors include SymBiosis.